ViroPharma Incorporated today announced that its Phase 3 trial evaluating maribavir used as prophylaxis against cytomegalovirus (CMV) disease in liver transplant patients has been discontinued, and that all patients on study drug are being moved to the current standard of care.
The details can be read here.
No comments:
Post a Comment